Evaxion A/S (EVAX) Competitors $2.54 -0.13 (-4.87%) Closing price 07/15/2025 03:52 PM EasternExtended Trading$2.48 -0.06 (-2.36%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. NEUP, ME, ATHA, IBIO, MTVA, ALVR, SONN, NXTC, LPTX, and IMCCShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Neuphoria Therapeutics (NEUP), 23andMe (ME), Athira Pharma (ATHA), iBio (IBIO), MetaVia (MTVA), AlloVir (ALVR), Sonnet BioTherapeutics (SONN), NextCure (NXTC), Leap Therapeutics (LPTX), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Neuphoria Therapeutics 23andMe Athira Pharma iBio MetaVia AlloVir Sonnet BioTherapeutics NextCure Leap Therapeutics IM Cannabis Neuphoria Therapeutics (NASDAQ:NEUP) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation. Which has more risk and volatility, NEUP or EVAX? Neuphoria Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Which has better earnings & valuation, NEUP or EVAX? Evaxion A/S has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics$10K1,421.28-$15.49MN/AN/AEvaxion A/S$3.34M1.06-$10.57M-$1.16-2.19 Do insiders and institutionals believe in NEUP or EVAX? 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 0.7% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer NEUP or EVAX? In the previous week, Evaxion A/S had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Evaxion A/S and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat Evaxion A/S's score of 0.63 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neuphoria Therapeutics Very Positive Evaxion A/S Positive Is NEUP or EVAX more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Neuphoria Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria TherapeuticsN/A N/A N/A Evaxion A/S -316.03%-532.72%-78.32% Do analysts recommend NEUP or EVAX? Neuphoria Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 177.78%. Evaxion A/S has a consensus target price of $10.00, indicating a potential upside of 293.70%. Given Evaxion A/S's higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Neuphoria Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNeuphoria Therapeutics beats Evaxion A/S on 7 of the 13 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.74M$2.00B$5.61B$9.29BDividend YieldN/AN/A4.23%4.03%P/E Ratio-2.1934.2528.5419.58Price / Sales1.0615.04429.2495.01Price / CashN/A54.7436.0257.93Price / Book-2.158.258.145.54Net Income-$10.57M-$62.39M$3.24B$257.73M7 Day PerformanceN/A-2.22%0.18%-0.08%1 Month Performance5.83%9.89%5.96%8.09%1 Year Performance-84.13%3.14%26.24%13.02% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S2.7846 of 5 stars$2.54-4.9%$10.00+293.7%-83.9%$3.74M$3.34M-2.1960NEUPNeuphoria Therapeutics2.2195 of 5 stars$7.16+0.4%$21.00+193.3%N/A$13.40M$10K0.00N/AME23andMeN/A$0.50-35.3%N/A-94.9%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeATHAAthira Pharma3.4451 of 5 stars$0.33-2.9%$11.25+3,308.1%-88.2%$13.27MN/A-0.1640Positive NewsIBIOiBio1.2706 of 5 stars$0.78+5.9%$4.30+448.0%-68.4%$12.96M$375K0.00100MTVAMetaVia1.7218 of 5 stars$0.62-4.0%$7.50+1,105.6%N/A$12.69MN/A0.008ALVRAlloVirN/A$2.50-2.3%N/A-85.6%$12.61MN/A-0.12110High Trading VolumeSONNSonnet BioTherapeutics3.7511 of 5 stars$4.73+20.7%$20.00+322.8%+38.4%$12.41M$20K0.0010Trending NewsGap DownHigh Trading VolumeNXTCNextCure4.3572 of 5 stars$0.44+1.2%$3.50+693.5%+185.0%$12.22MN/A-0.2590Analyst ForecastLPTXLeap Therapeutics2.22 of 5 stars$0.28-2.6%$3.38+1,089.2%-84.6%$12.07MN/A-0.1740Positive NewsGap DownIMCCIM Cannabis0.1606 of 5 stars$3.30+11.5%N/A+11.9%$11.97M$39.44M-5.16340 Related Companies and Tools Related Companies Neuphoria Therapeutics Competitors 23andMe Competitors Athira Pharma Competitors iBio Competitors MetaVia Competitors AlloVir Competitors Sonnet BioTherapeutics Competitors NextCure Competitors Leap Therapeutics Competitors IM Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
